See more : Rio Tinto Group (RIO.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Aroa Biosurgery Limited (ARX.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aroa Biosurgery Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- Lazydays Holdings Inc (LAZYW) Income Statement Analysis – Financial Results
- Shenergy Company Limited (600642.SS) Income Statement Analysis – Financial Results
- Alfa, S. A. B. de C. V. (ALFAA.MX) Income Statement Analysis – Financial Results
- Glencore plc (GLEN.L) Income Statement Analysis – Financial Results
- Danske Invest – Global Sustainable Future 3 (DKIGSFUT3.CO) Income Statement Analysis – Financial Results
Aroa Biosurgery Limited (ARX.AX)
About Aroa Biosurgery Limited
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 63.36M | 59.31M | 36.88M | 20.51M | 23.83M | 21.77M | 9.66M |
| Cost of Revenue | 9.26M | 9.25M | 8.72M | 6.26M | 6.33M | 8.04M | 5.45M |
| Gross Profit | 54.10M | 50.06M | 28.17M | 14.25M | 17.50M | 13.73M | 4.21M |
| Gross Profit Ratio | 85.39% | 84.40% | 76.37% | 69.48% | 73.43% | 63.08% | 43.56% |
| Research & Development | 8.49M | 9.93M | 7.76M | 5.90M | 4.48M | 4.07M | 2.89M |
| General & Administrative | 597.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 57.01M | 44.66M | 28.54M | 19.98M | 0.00 | 0.00 | 0.00 |
| SG&A | 57.01M | 44.66M | 28.54M | 19.98M | 15.84M | 9.84M | 3.56M |
| Other Expenses | -1.53M | 3.30M | 1.16M | -4.30M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 54.10M | 58.19M | 39.22M | 28.70M | 20.32M | 13.91M | 6.45M |
| Cost & Expenses | 73.14M | 67.44M | 47.93M | 34.96M | 26.65M | 21.95M | 11.90M |
| Interest Income | 1.20M | 1.23M | 374.57K | 141.38K | 2.85K | 2.80K | 144.12K |
| Interest Expense | 1.16M | 5.62K | 697.09K | 1.38M | 228.04K | 2.57M | 62.82K |
| Depreciation & Amortization | 4.03M | 3.50M | 2.95M | 2.88M | 2.61M | 1.93M | 681.80K |
| EBITDA | -7.36M | 3.50M | -3.75M | -14.56M | -219.49K | 1.75M | -1.56M |
| EBITDA Ratio | -11.62% | 5.46% | -11.04% | -65.00% | -0.92% | 8.03% | -16.12% |
| Operating Income | -9.79M | -353.83K | -6.98M | -16.16M | -2.83M | -179.25K | -2.24M |
| Operating Income Ratio | -15.45% | -0.60% | -18.93% | -78.78% | -11.86% | -0.82% | -23.17% |
| Total Other Income/Expenses | 223.80K | 2.55M | -697.09K | -3.09M | -3.10M | -2.67M | 776.03K |
| Income Before Tax | -9.56M | -359.45K | -7.68M | -17.54M | -5.85M | -2.84M | -1.46M |
| Income Before Tax Ratio | -15.10% | -0.61% | -20.82% | -85.50% | -24.57% | -13.07% | -15.14% |
| Income Tax Expense | 184.39K | 11.23K | 116.18K | 98.23K | -191.94K | -3.74M | -284.55K |
| Net Income | -9.75M | -370.68K | -7.79M | -17.63M | -5.66M | 896.26K | -1.18M |
| Net Income Ratio | -15.39% | -0.63% | -21.13% | -85.98% | -23.76% | 4.12% | -12.20% |
| EPS | -0.03 | 0.00 | -0.02 | -0.06 | -0.02 | 0.00 | 0.00 |
| EPS Diluted | -0.03 | 0.00 | -0.02 | -0.06 | -0.02 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 343.83M | 342.92M | 342.16M | 300.40M | 300.07M | 300.07M | 300.07M |
| Weighted Avg Shares Out (Dil) | 343.83M | 342.92M | 342.16M | 300.40M | 300.07M | 300.07M | 300.07M |
Source: https://incomestatements.info
Category: Stock Reports